PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
Amand F. Schmidt,Lucy S Pearce,John T. Wilkins,John P. Overington,Aroon D. Hingorani,Juan P. Casas +5 more
TLDR
A large number of trials randomised participants to alirocumab, three trials to bococizumab, one to RG7652, and four to evolocumab found that PCSK9 inhibitors appeared to have a stronger protective effect on CVD risk, although with considerable uncertainty.Abstract:
Background
Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may be warranted, especially for patients who are unresponsive to, or unable to take, existing LDL-C-reducing therapies. By inhibiting the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, monoclonal antibodies (PCSK9 inhibitors) may further reduce LDL-C, potentially reducing CVD risk as well.
Objectives
Primary
To quantify short-term (24 weeks), medium-term (one year), and long-term (five years) effects of PCSK9 inhibitors on lipid parameters and on the incidence of CVD.
Secondary
To quantify the safety of PCSK9 inhibitors, with specific focus on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, to determine if specific patient subgroups were more or less likely to benefit from the use of PCSK9 inhibitors.
Search methods
We identified studies by systematically searching the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and Web of Science. We also searched Clinicaltrials.gov and the International Clinical Trials Registry Platform and screened the reference lists of included studies. We identified the studies included in this review through electronic literature searches conducted up to May 2016, and added three large trials published in March 2017.
Selection criteria
All parallel-group and factorial randomised controlled trials (RCTs) with a follow-up time of at least 24 weeks were eligible.
Data collection and analysis
Two review authors independently reviewed and extracted data. When data were available, we calculated pooled effect estimates.
Main results
We included 20 studies with data on 67,237 participants (median age 61 years; range 52 to 64 years). Twelve trials randomised participants to alirocumab, three trials to bococizumab, one to RG7652, and four to evolocumab. Owing to the small number of trials using agents other than alirocumab, we did not differentiate between types of PCSK9 inhibitors used. We compared PCSK9 inhibitors with placebo (thirteen RCTs), ezetimibe (two RCTs) or ezetimibe and statins (five RCTs).
Compared with placebo, PCSK9 inhibitors decreased LDL-C by 53.86% (95% confidence interval (CI) 58.64 to 49.08; eight studies; 4782 participants; GRADE: moderate) at 24 weeks; compared with ezetimibe, PCSK9 inhibitors decreased LDL-C by 30.20% (95% CI 34.18 to 26.23; two studies; 823 participants; GRADE: moderate), and compared with ezetimibe and statins, PCSK9 inhibitors decreased LDL-C by 39.20% (95% CI 56.15 to 22.26; five studies; 5376 participants; GRADE: moderate).
Compared with placebo, PCSK9 inhibitors decreased the risk of CVD events, with a risk difference (RD) of 0.91% (odds ratio (OR) of 0.86, 95% CI 0.80 to 0.92; eight studies; 59,294 participants; GRADE: moderate). Compared with ezetimibe and statins, PCSK9 inhibitors appeared to have a stronger protective effect on CVD risk, although with considerable uncertainty (RD 1.06%, OR 0.45, 95% CI 0.27 to 0.75; three studies; 4770 participants; GRADE: very low). No data were available for the ezetimibe only comparison. Compared with placebo, PCSK9 probably had little or no effect on mortality (RD 0.03%, OR 1.02, 95% CI 0.91 to 1.14; 12 studies; 60,684 participants; GRADE: moderate). Compared with placebo, PCSK9 inhibitors increased the risk of any adverse events (RD 1.54%, OR 1.08, 95% CI 1.04 to 1.12; 13 studies; 54,204 participants; GRADE: low). Similar effects were observed for the comparison of ezetimibe and statins: RD 3.70%, OR 1.18, 95% CI 1.05 to 1.34; four studies; 5376 participants; GRADE: low. Clinical event data were unavailable for the ezetimibe only comparison.
Authors' conclusions
Over short-term to medium-term follow-up, PCSK9 inhibitors reduced LDL-C. Studies with medium-term follow-up time (longest median follow-up recorded was 26 months) reported that PCSK9 inhibitors (compared with placebo) decreased CVD risk but may have increased the risk of any adverse events (driven by SPIRE-1 and -2 trials). Available evidence suggests that PCSK9 inhibitor use probably leads to little or no difference in mortality. Evidence on relative efficacy and safety when PCSK9 inhibitors were compared with active treatments was of low to very low quality (GRADE); follow-up times were short and events were few. Large trials with longer follow-up are needed to evaluate PCSK9 inhibitors versus active treatments as well as placebo. Owing to the predominant inclusion of high-risk patients in these studies, applicability of results to primary prevention is limited. Finally, estimated risk differences indicate that PCSK9 inhibitors only modestly change absolute risks (often to less than 1%).read more
Citations
More filters
Journal ArticleDOI
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Emelia J. Benjamin,Paul Muntner,Alvaro Alonso,Márcio Sommer Bittencourt,Clifton W. Callaway,April P. Carson,Alanna M. Chamberlain,Alex R. Chang,Susan Cheng,Sandeep R Das,Francesca N. Delling,Luc Djoussé,Mitchell S.V. Elkind,Jane F. Ferguson,Myriam Fornage,Lori C. Jordan,Sadiya S. Khan,Brett M. Kissela,Kristen L. Knutson,Tak W. Kwan,Daniel T. Lackland,Tené T. Lewis,Judith H. Lichtman,Chris T. Longenecker,Matthew Shane Loop,Pamela L. Lutsey,Seth S. Martin,Kunihiro Matsushita,Andrew E. Moran,Michael E. Mussolino,Martin O'Flaherty,Ambarish Pandey,Amanda M. Perak,Wayne D. Rosamond,Gregory A. Roth,Uchechukwu K.A. Sampson,Gary Satou,Emily B. Schroeder,Svati H. Shah,Nicole L. Spartano,Andrew Stokes,David L. Tirschwell,Connie W. Tsao,Mintu P. Turakhia,Lisa B. VanWagner,John T. Wilkins,Sally S. Wong,Salim S. Virani +47 more
TL;DR: March 5, 2019 e1 WRITING GROUP MEMBERS Emelia J. Virani, MD, PhD, FAHA, Chair Elect On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee.
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
François Mach,Colin Baigent,Alberico L. Catapano,Konstantinos C. Koskinas,Manuela Casula,Lina Badimon,M. John Chapman,Guy De Backer,Victoria Delgado,Brian A. Ference,Ian D. Graham,Alison Halliday,Ulf Landmesser,Borislava Mihaylova,Terje R. Pedersen,Gabriele Riccardi,Dimitrios J. Richter,Marc S. Sabatine,Marja-Riitta Taskinen,Lale Tokgozoglu,Olov Wiklund,Christian Mueller,Heinz Drexel,Victor Aboyans,Alberto Corsini,Wolfram Doehner,Michel Farnier,Bruna Gigante,Meral Kayıkçıoğlu,Goran Krstacic,Ekaterini Lambrinou,Basil S. Lewis,Josep Masip,Philippe Moulin,Steffen E. Petersen,Anna Sonia Petronio,Massimo F Piepoli,Xavier Pintó,Lorenz Räber,Kausik K. Ray,Željko Reiner,Walter F Riesen,Marco Roffi,Jean-Paul Schmid,Evgeny Shlyakhto,Iain A. Simpson,Erik S.G. Stroes,Isabella Sudano,Alexandros D Tselepis,Margus Viigimaa,Cecile Vindis,Alexander Vonbank,Michal Vrablik,Mislav Vrsalovic,José Luis Zamorano,Jean-Philippe Collet,Stephan Windecker,Veronica Dean,Donna Fitzsimons,Chris P Gale,Diederick E. Grobbee,Sigrun Halvorsen,Gerhard Hindricks,Bernard Iung,Peter Jüni,Hugo A. Katus,Christophe Leclercq,Maddalena Lettino,Béla Merkely,Miguel Sousa-Uva,Rhian M. Touyz,Djamaleddine Nibouche,Parounak H. Zelveian,Peter Siostrzonek,Ruslan Najafov,Philippe van de Borne,Belma Pojskic,Arman Postadzhiyan,Lambros Kypris,Jindřich Špinar,Mogens Lytken Larsen,Hesham Salah Eldin,Timo E. Strandberg,Jean Ferrières,Rusudan Agladze,Ulrich Laufs,Loukianos S. Rallidis,Laszlo Bajnok,Thorbjorn Gudjonsson,Vincent Maher,Yaakov Henkin,Michele Massimo Gulizia,Aisulu Mussagaliyeva,Gani Bajraktari,Alina Kerimkulova,Gustavs Latkovskis,Omar Hamoui,Rimvydas Šlapikas,Laurent Visser,P. Dingli,Victoria Ivanov,Aneta Boskovic,Mbarek Nazzi,Frank L.J. Visseren,Irena Mitevska,Kjetil Retterstøl,Piotr Jankowski,Ricardo Fontes-Carvalho,Dan Gaita,Marat V. Ezhov,Marina Foscoli,Vojislav Giga,Daniel Pella,Zlatko Fras,Leopoldo Pérez de Isla,Emil Hagström,Roger Lehmann,Leila Abid,Oner Ozdogan,Olena Mitchenko,Riyaz S. Patel +120 more
Journal ArticleDOI
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.
Juhani Knuuti,William Wijns,Antti Saraste,Davide Capodanno,Emanuele Barbato,Christian Funck-Brentano,Eva Prescott,Robert F. Storey,Christi Deaton,Thomas Cuisset,Stefan Agewall,Kenneth Dickstein,Thor Edvardsen,Javier Escaned,Bernard J. Gersh,Pavel Svitil,Martine Gilard,David Hasdai,Robert Hatala,Felix Mahfoud,Josep Masip,Claudio Muneretto,Marco Valgimigli,Stephan Achenbach,Jeroen J. Bax +24 more
TL;DR: In this article, the authors present guidelines for the management of patients with coronary artery disease (CAD), which is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries.
Journal ArticleDOI
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
Alison Halliday,Colin Baigent,François Mach,Borislava Mihaylova,Borislava Mihaylova,Brian A. Ference +5 more
TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
Journal ArticleDOI
Genetic drug target validation using Mendelian randomisation.
Amand F. Schmidt,Amand F. Schmidt,Chris Finan,María Gordillo-Marañón,Folkert W. Asselbergs,Folkert W. Asselbergs,Daniel F. Freitag,Riyaz S. Patel,Benoit Tyl,Sandesh Chopade,Rupert Faraway,Rupert Faraway,Magdalena Zwierzyna,Aroon D. Hingorani +13 more
TL;DR: A mathematical framework is introduced that contrasts MR analysis of proteins with that of risk factors located more distally in the causal chain from gene to disease, which has potential to aid drug development.
References
More filters
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.
Journal ArticleDOI
Grading quality of evidence and strength of recommendations.
David C. Atkins,Dana Best,Peter A. Briss,Martin P Eccles,Yngve Falck-Ytter,Signe Flottorp,Gordon H. Guyatt,Robin Harbour,Margaret C Haugh,David Henry,Suzanne Hill,Roman Jaeschke,Gillian Leng,Alessandro Liberati,Nicola Magrini,James Mason,Philippa Middleton,Jacek Mrukowicz,Dianne L. O'Connell,Andrew D Oxman,Bob Phillips,Holger J. Schünemann,Tessa Tan-Torres Edejer,H. Varonen,Gunn Elisabeth Vist,John W Williams,Stephanie Zaza +26 more
TL;DR: A system for grading the quality of evidence and the strength of recommendations that can be applied across a wide range of interventions and contexts is developed, and a summary of the approach from the perspective of a guideline user is presented.
Journal Article
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 (vol 380, pg 2197, 2012)
TL;DR: In this article, a comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injury-specific epidemiology has been done since the 1990 study, and the authors aimed to calculate disease burden globally and for 21 regions for 1990, 2005, and 2010 with methods to enable meaningful comparisons over time.
Journal ArticleDOI
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Scott M. Grundy,James I. Cleeman,C. Noel Bairey Merz,H. Bryan Brewer,Luther T. Clark,Donald B. Hunninghake,Richard C. Pasternak,Sidney C. Smith,Neil J. Stone +8 more
TL;DR: The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL, and confirm that older persons benefit from therapeutic lowering of LDL-C.
Journal ArticleDOI
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J L Murray,Theo Vos,Rafael Lozano,Mohsen Naghavi,Abraham D. Flaxman,Catherine Michaud,Majid Ezzati,Kenji Shibuya,Joshua A. Salomon,Safa Abdalla,Victor Aboyans,Jerry Abraham,Ilana N. Ackerman,Rakesh Aggarwal,Stephanie Y. Ahn,Mohammed K. Ali,Mohammad A. AlMazroa,Miriam Alvarado,H. Ross Anderson,Laurie M. Anderson,Kathryn G. Andrews,Charles Atkinson,Larry M. Baddour,Adil N. Bahalim,Suzanne Barker-Collo,Lope H Barrero,David Bartels,María-Gloria Basáñez,Amanda J Baxter,Michelle L. Bell,Emelia J. Benjamin,Derrick A Bennett,Eduardo Bernabé,Kavi Bhalla,Bishal Bhandari,Boris Bikbov,Aref A. Bin Abdulhak,Gretchen L. Birbeck,James A. Black,Hannah Blencowe,Jed D. Blore,Fiona M. Blyth,Ian Bolliger,Audrey Bonaventure,Soufiane Boufous,Rupert R A Bourne,Michel Boussinesq,Tasanee Braithwaite,Carol Brayne,Lisa Bridgett,Simon Brooker,Peter Brooks,Traolach S. Brugha,Claire Bryan-Hancock,Chiara Bucello,Rachelle Buchbinder,Geoffrey Buckle,Christine M. Budke,Michael Burch,Peter Burney,Roy Burstein,Bianca Calabria,Benjamin L. Campbell,Charles E. Canter,Hélène Carabin,Jonathan R. Carapetis,Loreto Carmona,Claudia Cella,Fiona J Charlson,Honglei Chen,Andrew T. A. Cheng,David Chou,Sumeet S. Chugh,Luc E. Coffeng,Steven D. Colan,Samantha M. Colquhoun,K. Ellicott Colson,John R. Condon,Myles Connor,Myles Connor,Myles Connor,Leslie T. Cooper,Matthew A. Corriere,Monica Cortinovis,Karen Courville De Vaccaro,William G. Couser,Benjamin C Cowie,Michael H. Criqui,Marita Cross,Kaustubh Dabhadkar,Manu Dahiya,Nabila Dahodwala,James Damsere-Derry,Goodarz Danaei,Adrian Davis,Diego De Leo,Louisa Degenhardt,Louisa Degenhardt,Robert P. Dellavalle,Allyne Delossantos,Julie O. Denenberg,Sarah Derrett,Don C. Des Jarlais,Samath D Dharmaratne,Samath D Dharmaratne,Mukesh Dherani,Cesar Diaz-Torne,Helen Dolk,E. Ray Dorsey,Tim Driscoll,Herbert C. Duber,Beth E. Ebel,Karen Edmond,Alexis Elbaz,S. Ali,Holly E. Erskine,Patricia J. Erwin,Patricia Espindola,Stalin E. Ewoigbokhan,Farshad Farzadfar,Valery L. Feigin,David T. Felson,Alize J. Ferrari,Cleusa P. Ferri,Eric M. Fèvre,Mariel M. Finucane,Seth Flaxman,Louise Flood,Kyle J Foreman,Mohammad H. Forouzanfar,F.G.R. Fowkes,Marlene Fransen,Michael Freeman,Belinda J. Gabbe,Sherine E. Gabriel,Emmanuela Gakidou,Hammad A. Ganatra,Bianca Garcia,Flavio Gaspari,Richard F. Gillum,Gerhard Gmel,Diego Gonzalez-Medina,Richard A. Gosselin,Rebecca Grainger,Bridget F. Grant,Justina Groeger,Francis Guillemin,David Gunnell,R Gupta,Juanita A. Haagsma,Holly Hagan,Yara A. Halasa,Wayne Hall,Diana Haring,Josep Maria Haro,James Harrison,Rasmus Havmoeller,Rasmus Havmoeller,Roderick J. Hay,Hideki Higashi,Christopher Hill,Bruno Hoen,Howard J. Hoffman,Peter J. Hotez,Damian G Hoy,John J Huang,Sydney E. Ibeanusi,Kathryn H. Jacobsen,Spencer L. James,Deborah Jarvis,Rashmi Jasrasaria,Sudha Jayaraman,Nicole E. Johns,Jost B. Jonas,Ganesan Karthikeyan,Nicholas J Kassebaum,Norito Kawakami,Andre Keren,Jon Paul Khoo,Charles H. King,Lisa M. Knowlton,Olive Kobusingye,Olive Kobusingye,Adofo Koranteng,Rita Krishnamurthi,Francine Laden,Ratilal Lalloo,Laura L Laslett,Tim Lathlean,Janet L Leasher,Yong Yi Lee,James Leigh,Daphna Levinson,Stephen S Lim,Elizabeth S Limb,John K Lin,Michael S Lipnick,Steven E. Lipshultz,Wei Liu,Maria Loane,Summer Lockett Ohno,Ronan A Lyons,Jacqueline Mabweijano,Michael F. MacIntyre,Reza Malekzadeh,Leslie Mallinger,Sivabalan Manivannan,Wagner Marcenes,Lyn March,David J. Margolis,Guy B. Marks,Robin Marks,Akira Matsumori,Richard Matzopoulos,Richard Matzopoulos,Bongani M. Mayosi,John H. McAnulty,Mary M. McDermott,Neil McGill,John J. McGrath,María Elena Medina-Mora,Michele Meltzer,Ziad A. Memish,George A. Mensah,Tony R. Merriman,Ana-Claire Meyer,Valeria Miglioli,Matthew J. Miller,Ted R. Miller,Philip B. Mitchell,Charles Mock,Ana Olga Mocumbi,Terrie E. Moffitt,Ali A. Mokdad,Lorenzo Monasta,Marcella Montico,Maziar Moradi-Lakeh,Andrew E. Moran,Lidia Morawska,Rintaro Mori,Michele E. Murdoch,Michael K Mwaniki,Kovin Naidoo,M. Nathan Nair,Luigi Naldi,K.M. Venkat Narayan,Paul K. Nelson,Robert G. Nelson,Michael C. Nevitt,Charles R. Newton,Sandra Nolte,Paul Norman,Rosana E. Norman,Martin O'Donnell,Simon J. O’Hanlon,Casey Olives,Saad B. Omer,Katrina F Ortblad,Richard H. Osborne,Doruk Ozgediz,Andrew Page,Bishnu Pahari,Jeyaraj D Pandian,Andrea Panozo Rivero,Scott B. Patten,Neil Pearce,Rogelio Perez Padilla,Fernando Perez-Ruiz,Norberto Perico,Konrad Pesudovs,David Phillips,Michael Phillips,Kelsey Pierce,Sébastien D. S. Pion,Guilherme V. Polanczyk,Suzanne Polinder,C. Arden Pope,Svetlana Popova,Esteban Porrini,Farshad Pourmalek,Martin Prince,Rachel L. Pullan,Kapa D. Ramaiah,Dharani Ranganathan,Homie Razavi,Mathilda Regan,Jürgen Rehm,David B. Rein,G. Remuzzi,Kathryn Richardson,Frederick P. Rivara,Thomas Roberts,Carolyn Robinson,Felipe Rodriguez De Leòn,Luca Ronfani,Robin Room,Robin Room,Lisa C. Rosenfeld,Lesley Rushton,Ralph L. Sacco,Sukanta Saha,Uchechukwu Sampson,Lidia Sanchez-Riera,Ella Sanman,David C. Schwebel,James Scott,Maria Segui-Gomez,Saeid Shahraz,Donald S. Shepard,Hwashin Shin,Rupak Shivakoti,Donald H. Silberberg,David Singh,Gitanjali M Singh,Jasvinder A. Singh,Jessica Singleton,David A. Sleet,Karen Sliwa,Emma Smith,Jennifer L. Smith,Nicolas J. C. Stapelberg,Andrew C Steer,Timothy J. Steiner,Wilma A. Stolk,Lars Jacob Stovner,Christopher R. Sudfeld,Sana Syed,Giorgio Tamburlini,Mohammad Tavakkoli,Hugh R. Taylor,Jennifer A. Taylor,William J. Taylor,Bernadette Thomas,W. Murray Thomson,George D. Thurston,Imad M. Tleyjeh,Marcello Tonelli,Jeffrey A. Towbin,Thomas Truelsen,Miltiadis K. Tsilimbaris,Clotilde Ubeda,Eduardo A. Undurraga,Marieke J. van der Werf,Jim van Os,Monica S. Vavilala,Narayanaswamy Venketasubramanian,Mengru Wang,Wenzhi Wang,Kerrianne Watt,David J. Weatherall,Martin A. Weinstock,Robert G. Weintraub,Marc G. Weisskopf,Myrna M. Weissman,Richard A. White,Harvey Whiteford,Natasha Wiebe,Steven T. Wiersma,James D. Wilkinson,Hywel C Williams,Sean R.M. Williams,Emma Witt,Frederick Wolfe,Anthony D. Woolf,Sarah Wulf,Pon Hsiu Yeh,Anita K. M. Zaidi,Zhi Jie Zheng,David Zonies,Alan D. Lopez +369 more
TL;DR: The results for 1990 and 2010 supersede all previously published Global Burden of Disease results and highlight the importance of understanding local burden of disease and setting goals and targets for the post-2015 agenda taking such patterns into account.
Related Papers (5)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.
Marianne Abifadel,Mathilde Varret,Jean-Pierre Rabès,Delphine Allard,Khadija Ouguerram,Martine Devillers,Corinne Cruaud,Suzanne Benjannet,Louise Wickham,D. Erlich,Aurélie Derré,Ludovic Villéger,Michel Farnier,Isabel Beucler,Eric Bruckert,Jean Chambaz,Bernard Chanu,Jean-Michel Lecerf,Gérald Luc,Philippe Moulin,Jean Weissenbach,Annick Prat,Michel Krempf,Claudine Junien,Nabil G. Seidah,Catherine Boileau +25 more